EMAIL THIS PAGE TO A FRIEND

The American journal of pathology

Neuronal cell death in the inner retina and the influence of vascular endothelial growth factor inhibition in a diabetic rat model.


PMID 24709590

Abstract

To inhibit vascular changes in diabetic retinopathy, inhibiting vascular endothelial growth factor (VEGF) has become a mainstay of the treatment of diabetic retinopathy. However, its effects on neuronal cells remain to be elucidated. We aimed to evaluate the effect of VEGF inhibition on neuronal cells in a streptozotocin-induced diabetic rat retina. VEGF inhibition was performed by intravitreal VEGF-A antibody injection. After anti-VEGF treatment, apoptosis in retinal ganglion cells (RGCs) increased, and novel apoptosis in amacrine and bipolar cells of the inner nuclear layer was observed by TUNEL staining. Phosphorylated Akt expression was significantly higher in RGCs but was decreased in neuronal cells of the inner nuclear layer after anti-VEGF treatment by Western blot analysis and immunohistochemical staining. These results demonstrate that VEGF inhibition significantly increased RGC apoptosis and neuronal cell apoptosis in the inner nuclear layer of a diabetic retina, which seems to consist primarily of amacrine and bipolar cells. The phosphorylated Akt pathway, which plays a neuroprotective role via VEGF, was significantly affected by VEGF inhibition in the inner nuclear layer, suggesting that neurotrophic factor deprivation is the main mechanism for neuronal cell death after inhibiting VEGF. The results of this study show that inhibiting VEGF may have detrimental effects on the apoptosis of neuronal cells in the inner layers of the diabetic retina.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB2105686
Anti-A4GALT antibody produced in rabbit, affinity isolated antibody, lyophilized powder
SAB1306766 ANTI-MAP3K12 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB1306765
ANTI-MAP3K12 antibody produced in mouse, crude ascites, buffered aqueous solution
SAB2700169
Anti-Map3k12 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
HPA039936 Anti-MAP3K12 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2500752
Anti-Parvalbumin antibody produced in goat, affinity isolated antibody, buffered aqueous solution
HPA048536
Anti-PVALB antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1300426 Anti-ZPK (center) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
WH0053947M8 Monoclonal Anti-A4GALT antibody produced in mouse, clone 3E12, purified immunoglobulin, buffered aqueous solution
SAB4200545
Monoclonal Anti-Parvalbumin antibody produced in mouse, ~1.0 mg/mL, clone PARV-19, purified immunoglobulin
X1251
Xylazine hydrochloride, ≥99%
C12H16N2S · HCl
46995
Xylazine hydrochloride, VETRANAL, analytical standard
C12H16N2S · HCl
X0075000
Xylazine hydrochloride, European Pharmacopoeia (EP) Reference Standard
C12H16N2S · HCl